{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["31(7)"],"submitter":["Zhou C"],"funding":["F. Hoffman-La Roche, Inc."],"pubmed_abstract":["After the global approval of atezolizumab plus bevacizumab and chemotherapy as first-line metastatic nonsquamous non-small-cell lung cancer (nsqNSCLC) treatment, the IMpower151 ( NCT04194203 ) trial was conducted in China to address regional differences. Chemotherapy-naive patients with metastatic nsqNSCLC (N = 305) were randomized 1:1 to receive either atezolizumab, bevacizumab, carboplatin and paclitaxel or pemetrexed (ABCPem/Pac; n = 152) or placebo plus bevacizumab, carboplatin and pemetrexed or paclitaxel (BCPem/Pac; n = 153). The primary endpoint was investigator-assessed progression-free survival (INV-PFS); secondary endpoints included subgroup analyses of INV-PFS, independent review facility-assessed PFS, overall survival, and investigator-assessed objective response rate and durat"],"journal":["Nature medicine"],"pagination":["2375-2384"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12283377"],"repository":["biostudies-literature"],"pubmed_title":["Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial."],"pmcid":["PMC12283377"],"pubmed_authors":["Dong X","Wu Q","Sun C","Cai J","Cheng Y","Wang L","Wang M","Yao Y","Wang Q","Zhou C","Chen X","Ballinger M","Wang Z","Wu X","Srivastava MK","Xu M","He J","Cui J","Chen G","Pan H","Li X","Kaul M","Zhang Y","Zhang X","Huang X","Yan I","Qian L"],"additional_accession":[]},"is_claimable":false,"name":"Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial.","description":"After the global approval of atezolizumab plus bevacizumab and chemotherapy as first-line metastatic nonsquamous non-small-cell lung cancer (nsqNSCLC) treatment, the IMpower151 ( NCT04194203 ) trial was conducted in China to address regional differences. Chemotherapy-naive patients with metastatic nsqNSCLC (N = 305) were randomized 1:1 to receive either atezolizumab, bevacizumab, carboplatin and paclitaxel or pemetrexed (ABCPem/Pac; n = 152) or placebo plus bevacizumab, carboplatin and pemetrexed or paclitaxel (BCPem/Pac; n = 153). The primary endpoint was investigator-assessed progression-free survival (INV-PFS); secondary endpoints included subgroup analyses of INV-PFS, independent review facility-assessed PFS, overall survival, and investigator-assessed objective response rate and durat","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-03-16T05:29:32.433Z","creation":"2025-08-14T03:06:12.547Z"},"accession":"S-EPMC12283377","cross_references":{"pubmed":["40379995"],"doi":["10.1038/s41591-025-03658-y"]}}